SG Americas Securities LLC Sells 92,294 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

SG Americas Securities LLC trimmed its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 88.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,128 shares of the company's stock after selling 92,294 shares during the period. SG Americas Securities LLC's holdings in Hims & Hers Health were worth $358,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Raymond James Financial Inc. acquired a new stake in Hims & Hers Health in the 4th quarter valued at $18,048,000. O Shaughnessy Asset Management LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $208,000. Commonwealth Equity Services LLC raised its holdings in Hims & Hers Health by 111.6% during the fourth quarter. Commonwealth Equity Services LLC now owns 58,894 shares of the company's stock worth $1,424,000 after acquiring an additional 31,062 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Hims & Hers Health by 51.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 17,225 shares of the company's stock valued at $417,000 after purchasing an additional 5,885 shares during the last quarter. Finally, Amundi boosted its position in Hims & Hers Health by 49.1% during the fourth quarter. Amundi now owns 12,741 shares of the company's stock valued at $328,000 after purchasing an additional 4,197 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 36,460 shares of the business's stock in a transaction that occurred on Wednesday, April 16th. The shares were sold at an average price of $28.04, for a total transaction of $1,022,338.40. Following the completion of the transaction, the chief executive officer now directly owns 92,103 shares in the company, valued at $2,582,568.12. The trade was a 28.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Oluyemi Okupe sold 11,581 shares of the business's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $29.26, for a total value of $338,860.06. Following the transaction, the chief financial officer now directly owns 124,104 shares of the company's stock, valued at $3,631,283.04. This trade represents a 8.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold 706,454 shares of company stock valued at $35,220,112 in the last three months. Corporate insiders own 13.71% of the company's stock.

Hims & Hers Health Price Performance

NYSE HIMS traded up $3.15 on Friday, reaching $49.43. The stock had a trading volume of 83,270,134 shares, compared to its average volume of 23,090,246. The company has a market cap of $11.06 billion, a P/E ratio of 107.63, a price-to-earnings-growth ratio of 1.74 and a beta of 2.09. The firm has a fifty day moving average of $49.65 and a two-hundred day moving average of $39.46. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The business had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. During the same quarter in the previous year, the company earned $0.05 EPS. The business's revenue was up 110.7% on a year-over-year basis. Research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HIMS has been the topic of a number of analyst reports. UBS Group set a $30.00 price objective on Hims & Hers Health in a research note on Monday. Piper Sandler reaffirmed a "neutral" rating and set a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. TD Cowen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their price objective for the company from $44.00 to $30.00 in a research report on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Finally, Bank of America raised their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a research note on Tuesday, April 29th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $38.31.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.